Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Modeling trajectories of regional volume loss in progressive supranuclear palsy
Josephs, Keith A. , Xia, Rong, Mandrekar, Jay , Gunter, Jeffrey L. , Senjem, Matthew L. , Whitwell, Jennifer L. , Jack, Clifford R. , Senjem, Matthew L

Movement Disorders | April 8, 2013 | Volume: 28 | Issue: 8 | Pages: 1117-1124

10.1002/mds.25437 | PMID 23568852 Get It

ABSTRACTProgressive supranuclear palsy is a neurodegenerative disease with progressive brain atrophy over time. It is unknown which specific brain regions decline over time, whether regional volume loss occurs in a linear fashion, and whether regional atrophy correlates with clinical decline over time in progressive supranuclear palsy. Twenty‐eight subjects meeting probable progressive supranuclear palsy criteria were prospectively recruited and completed 96 MRI scans over 2 years. Mixed‐effect models were utilized to determine which regions had significant atrophy over time and whether decline was linear or nonlinear. We assessed 13 regions across the brain, as well as whole‐brain and ventricular volume. Regional trajectories were also correlated with change in clinical measures of executive function and gait and ocular motor impairment. A linear decline was observed in all frontal and temporal regions, the superior parietal lobe, the thalamus, the caudate nuclei, and the midbrain, as well as in the whole brain. Ventricular expansion was also linear. Nonlinear decline was observed for the caudal middle frontal lobe and globus pallidus. Rates of change in the superior frontal lobe, thalamus, and midbrain were beyond those expected in normal aging. Decline in frontal lobe volume and the midbrain area correlated best to decline in clinical measures. In progressive supranuclear palsy, atrophy is occurring in multiple brain regions, particularly in those that have previously been implicated in the disease. Decline is mainly linear but can be nonlinear for some regions. The frontal lobe and midbrain seem to be playing the most significant roles in the progressive worsening of clinical signs in progressive supranuclear palsy. © 2013 Movement Disorder Society
Faculty Opinions recommendation of Neonatal epithelial hypoxia inducible factor-1α expression regulates the response of the lung to experimental asthma.
Britt, Rodney D. , Prakash, Y. S.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 8, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717991578.793473407 Get It

Impact of SAMMPRIS on the future of intracranial atherosclerotic disease management: polling results from the ICAD symposium at the International Stroke Conference
Zaidat, Osama O. , Castonguay, Alicia C. , Nguyen, Thanh N. , Becker, Kyra J. , Derdeyn, Colin P. , Nelson, Peter Kim , Amarenco, Pierre , Brott, Thomas G. , Nguyen, Thanh N , Derdeyn, Colin P

Journal of NeuroInterventional Surgery | April 6, 2013 | Volume: 6 | Issue: 3 | Pages: 225-230

10.1136/neurintsurg-2013-010667 | PMID 23563478 Get It

Objective There are few data regarding the effect of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial results on the management of intracranial atherosclerotic disease (ICAD). We sought to understand the impact of the SAMMPRIS trial on current ICAD clinical practices and future trial design. Methods During the ICAD symposium at the 2012 International Stroke Conference, electronic data were collected regarding attendees’ clinical management of ICAD and opinions on the feasibility of future trials post-SAMMPRIS. Results 217 attendees from different specialties, including neurologists (57%), neurointerventionalists (9%) and neurosurgeons (5%), participated in the session. The majority of respondents (77%) indicated that the results of SAMMPRIS have impacted their consideration for intracranial stenting. Post-SAMMPRIS, 84% selected ‘SAMMPRIS-style’ medical management for the treatment of ICAD. For patients with ICAD who failed aggressive medical therapy, 82% would consider an alternative approach to continuing medical therapy (30% considered clinical trial enrollment, 28% suggested angioplasty and stenting and 24% angioplasty). The majority of participants (85%) were willing to randomize patients with symptomatic ICAD in future trials. For the next ICAD trial, 29% indicated that angioplasty alone should be compared with aggressive medical therapy. Conclusions Our polling results suggest that the SAMMPRIS trial has had an impact on the current treatment of ICAD. Treatment of patients who failed medical therapy varied widely from aggressive medical therapy to balloon angioplasty, stenting or enrollment in future clinical trials. The willingness to continue clinical trials and randomize patients supports the need for future ICAD studies.
Contemporary Ventilator Management in Patients With and at Risk of ALI/ARDS
Chang, Steven Y., Dabbagh, Ousama, Gajic, O, Patrawalla, Amee , Elie, Marie‐Carmelle , Talmor, Daniel , Malhotra, Atul , Adesanya, Adebola, Anderson, Harry L, Blum, James M. , Park, Pauline K. , Gong, Michelle N. , (USCIITG-LIPS), on behalf of the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, (USCIITG-LIPS), the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, Talmor, Daniel S, Bender, S Patrick, Garcia, Mauricio, Hou, Peter C, Barry, Jonathan M, Shempp, Iam, Malhotra, Atul, Frendl, Gyorgy, Ahmed, Adil, Gajic, Ognjen, Malinchoc, Michael, Kor, Daryl J, Afessa, Bekele, Cartin-Ceba, Rodrigo, Gong, Michelle Ng, Gentile, Nina T, Stevenson, Karen, Freeman, Brent, Srinivasan, Sujatha, Sevransky, Jonathan, Chang, Steven Y, Patrawalla, Amee, Elie, Carmelle, Hamdani, Irram, Seiden, Jason, Douglas, Ivor, Mikkelsen, Mark, Christie, Jason D, Gaieski, David F, Lanken, Paul, Meyer, Nuala, Sha, Chirag, Park, Pauline K, Harris, Julie, Napolitano, Lena, Raghavendran, Krishnan, Hyzy, Robert C, Blum, James, Watkins, Timothy R, Deem, Steven, Treggiari, Miriam, Adesanya, Adebola, Sadikot, Ruxana, Hoth, J Jason, Yoza, Barbara, Festic, Emir, Kaufman, David, Bajwa, Ednan, Malhotra, Atul, Thompson, B Taylor, Christiani, David C, Cengiz, Melike, Yilmaz, Murat, Anderson, Harry, Tchorz, Kathryn, McCarthy, Mary C, Uddin, David, Iscimen, Remzi, Dabbagh, Ousama, Kallenbach, Nena, Esper, Anette, Martin, Greg, Bajwa, Ednan K. , Douglas, Ivor S. , Frendl, György , Chang, Steven Y. , Anderson, Harry L, (USCIITG-LIPS), on behalf of the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, (USCIITG-LIPS), the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, Talmor, Daniel S, Bender, S Patrick, Garcia, Mauricio, Hou, Peter C, Barry, Jonathan M, Shempp, Iam, Malhotra, Atul, Frendl, Gyorgy, Ahmed, Adil, Gajic, Ognjen, Malinchoc, Michael, Kor, Daryl J, Afessa, Bekele, Cartin-Ceba, Rodrigo, Gong, Michelle Ng, Gentile, Nina T, Stevenson, Karen, Freeman, Brent, Srinivasan, Sujatha, Sevransky, Jonathan, Chang, Steven Y, Patrawalla, Amee, Elie, Carmelle, Hamdani, Irram, Seiden, Jason, Douglas, Ivor, Mikkelsen, Mark, Christie, Jason D, Gaieski, David F, Lanken, Paul, Meyer, Nuala, Sha, Chirag, Park, Pauline K, Harris, Julie, Napolitano, Lena, Raghavendran, Krishnan, Hyzy, Robert C, Blum, James, Watkins, Timothy R, Deem, Steven, Treggiari, Miriam, Adesanya, Adebola, Sadikot, Ruxana, Hoth, J Jason, Yoza, Barbara, Festic, Emir, Kaufman, David, Bajwa, Ednan, Malhotra, Atul, Thompson, B Taylor, Christiani, David C, Cengiz, Melike, Yilmaz, Murat, Anderson, Harry, Tchorz, Kathryn, McCarthy, Mary C, Uddin, David, Iscimen, Remzi, Dabbagh, Ousama, Kallenbach, Nena, Esper, Anette, Martin, Greg

Respiratory Care | April 6, 2013 | Volume: 58 | Issue: 4 | Pages: 578-588

10.4187/respcare.01755 | PMID 22906363 Get It

Hepatic Cirrhosis Secondary to Nonalcoholic Fatty Liver Disease in a 12-Year-Old Girl With Morbid Obesity
Sharma, Animesh, Freese, Deborah K., Chandan, Vishal S. , Zarroug, Abdalla E., Swain, James , Kumar, Seema

Clinical Pediatrics | April 6, 2013 | Volume: 53 | Issue: 1 | Pages: 86-88

10.1177/0009922813483171 | PMID 23564302 Get It

How can we help children after mild traumatic brain injury?
Mack, Kenneth J.

Developmental Medicine & Child Neurology | April 5, 2013 | Volume: 55 | Issue: 7 | Pages: 588-589

10.1111/dmcn.12145 | PMID 23560778 Get It

This commentary is on the original article by Kuczynski et al. on pages 636–641 of this issue.
Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague–Dawley rats
Katayama, Minako , Jiamsripong, Panupong, Bukatina, A. E., Lombari, Theresa R, McMahon, Eileen M. , Gades, Naomi M. , Bëlohlávek, Marek

Laboratory Animals | April 5, 2013 | Volume: 47 | Issue: 2 | Pages: 122-126

10.1177/0023677213476864 | PMID 23563365 Get It

Pharmacokinetics of drugs may differ between small and large mammals (including humans); therefore, drug testing in animal models must be carefully designed. Sprague–Dawley rats were used in cardiac experiments, during which the lopinavir concentration in serum had to match human therapeutic levels (4–10 μg/mL). Lopinavir was administered as a co-formulated drug of lopinavir and ritonavir. It was found that after a single administration of a standard human peroral dose (lopinavir 13.3 mg/kg of body weight), the serum concentration of lopinavir was only one-tenth of the target level. It remained below the minimum target level even after 10-fold the standard dose was administered. After initial pilot tests, a dose escalation study was conducted with oral doses 10- and 15-fold the standard clinical dose of lopinavir (i.e. 133 and 200 mg/kg, respectively). A second administration 2 h later effectively increased and maintained higher concentrations during the experimental ischaemia and reperfusion periods. A dose-dependent increase in serum concentration of the drug was observed. Thus, the target therapeutic serum level of lopinavir in the rats was achieved by administrating 10- to 15-fold the standard human dose twice, separated by a 2 h interval.
Feasibility of a Clinical Trial of Vision Therapy for Treatment of Amblyopia
Lyon, Don, Hopkins, Kristine B., Chu, Raymond, Tamkins, Susanna M. , Melia, B. Michele, Holmes, Jonathan M. , Repka, Michael X. , Wheeler, David T., Sala, Nicholas A., Dumas, Janette, Silbert, David I., Group, the Pediatric Eye Disease Investigator, Kulp, Marjean Taylor , Cotter, Susan A. , Group, the Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Optometry and Vision Science | April 5, 2013 | Volume: 90 | Issue: 5 | Pages: 475-481

10.1097/opx.0b013e31828def04 | PMID 23563444 Get It

ABSTRACT Purpose We conducted a pilot randomized clinical trial of office‐based active vision therapy for the treatment of childhood amblyopia to determine the feasibility of conducting a full‐scale randomized clinical trial. Methods A training and certification program and manual of procedures were developed to certify therapists to administer a standardized vision therapy program in ophthalmology and optometry offices consisting of weekly visits for 16 weeks. Nineteen children, aged 7 to less than 13 years, with amblyopia (20/40–20/100) were randomly assigned to receive either 2 hours of daily patching with active vision therapy or 2 hours of daily patching with placebo vision therapy. Results Therapists in diverse practice settings were successfully trained and certified to perform standardized vision therapy in strict adherence with protocol. Subjects completed 85% of required weekly in‐office vision therapy visits. Eligibility criteria based on age, visual acuity, and stereoacuity, designed to identify children able to complete a standardized vision therapy program and judged likely to benefit from this treatment, led to a high proportion of screened subjects being judged ineligible, resulting in insufficient recruitment. There were difficulties in retrieving adherence data for the computerized home therapy procedures. Conclusions This study demonstrated that a 16‐week treatment trial of vision therapy was feasible with respect to maintaining protocol adherence; however, recruitment under the proposed eligibility criteria, necessitated by the standardized approach to vision therapy, was not successful. A randomized clinical trial of in‐office vision therapy for the treatment of amblyopia would require broadening of the eligibility criteria and improved methods to gather objective data regarding the home therapy. A more flexible approach that customizes vision therapy based on subject age, visual acuity, and stereopsis might be required to allow enrollment of a broader group of subjects.
West nile virus infection and myasthenia gravis
Leis, A. Arturo , Szatmáry, Gabriella, Ross, Mark A., Stokić, Dobrivoje S.

Muscle & Nerve | April 5, 2013 | Volume: 49 | Issue: 1 | Pages: 26-29

10.1002/mus.23869 | PMID 23559196 Get It